Title: Effect of “Yinzhi Decoction” Combined with Entecavir in Treating HBeAg Positive Chronic Hepatitis B
Abstract: Objective: To evaluate the clinical efficacy of Yinzhi Decoction combined with entecavir in the treatment of HBeAg positive chronic hepatitis B. Methods: A total of 120 patients with HBeAg positive chronic hepatitis B were randomly divided into treatment group and control group,with 60 cases in each group. The patients in treatment group were treated withYinzhi Decoctioncombined with entecavir and the patients in control group were treated with entecavir,with a course of 18 months. The clinical effect of Chinese medical syndrome was evaluated,and the HBeAg negative rate,HBeAg /antiHBe serological response rate,ALT recovery rate and the log value of HBV-DNA were tested. Results: Eighteen months after treatment,the total effective rates of treatment group and control group were 86. 67% and 60. 00% respectively on the Chinese medical syndrome,and the effect of treatment group was better than that of control group( P 0. 01). Eighteen months after treatment and twelve months after follow-up,the HBeAg negative rate and HBeAg /antiHBe serological response rate of treatment group were higher than those of control group( P 0. 05). Three months,six months and twelve months after treatment,the ALT recovery rate of treatment group was higher than that of control group( P 0. 05). After treatment,the log values of HBV-DNA in both groups were obviously decreased( P 0. 01),and three months after treatment and twelve months after follow-up the log value of HBV-DNA of treatment group was lower than that of control group( P 0. 05). Conclusion:Yinzhi Decoctioncombined with entecavir can inhibit the HBV-DNA replication,enhance the HBeAg negative rate and HBeAg /antiHBe serological response rate,and improve the clinical syndrome in treating HBeAg positive chronic hepatitis B.
Publication Year: 2014
Publication Date: 2014-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot